Remission of psoriasis after treatment with interferon-alfa and 2-chlordeoxyadenosine for hairy cell leukemia.

Abstract

2-Chlordeoxyadenosine (2-CdA) is an antineoplastic/immunosuppressive agent used to treat hairy cell leukemia (HCL), chronic lymphocytic leukemia, and low-grade lymphomas. Its immunomodulatory properties, however, may allow its future use in the treatment of psoriasis. We report a patient with psoriasis and HCL who was treated for 1 week with continuous intravenous infusion of 2-CdA for recurring HCL. Both the psoriasis and the HCL cleared. Four years after 2-CdA treatment, the patient has psoriasis on only 1% of his body surface area. 2-CdA induces lymphocytopenia, which may explain the improvement in this patient's psoriasis.

• Authors: W Ilyas, D Myers, R Mann, M P Seraly
• Journal: Journal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 41 Issue 2 Pt 2 Pg. 316-8 (Aug 1999) ISSN: 0190-9622 [Print] United States
• PMID: 10426918 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Immunosuppressive Agents
• Interferon-alpha
• Cladribine

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cladribine (administration & dosage)
• Humans
• Immunosuppressive Agents (therapeutic use)
• Interferon-alpha (administration & dosage, adverse effects)
• Leukemia, Hairy Cell (complications, drug therapy)
• Male
• Psoriasis (complications, pathology)